Understanding the specific details of the mechanisms of YAP/TAZ activation and suppression and their transcription promotion in epidermal KCs would support drug development for hyperproliferative epidermal diseases and anti-cancer therapy, as well as for maintaining KC proliferation and stimulating wound healing in epidermolysis bullosa or chronic ischemic wounds due to diabetes. This evidence concerns the gene YAP1 and cancer.